Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning

[1]  B. Hyman,et al.  Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy , 2002, The Journal of Neuroscience.

[2]  Blair R. Leavitt,et al.  Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease , 2002, The Journal of Neuroscience.

[3]  K. Senior.  Dosing in phase II trial of Alzheimer's vaccine suspended , 2002, Lancet Neurology.

[4]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[5]  D. Holtzman,et al.  Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.

[6]  B Frangione,et al.  Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. , 2001, The American journal of pathology.

[7]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[8]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[9]  B. Solomon,et al.  Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[11]  M. Knapp,et al.  The TAPS Project. A report on 13 years of research, 1985-1998 , 2000 .

[12]  N. Trieman,et al.  Long-stay patients discharged from psychiatric hospitals , 2000, British Journal of Psychiatry.

[13]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[14]  G. Banerjee,et al.  Determinants of Help-Seeking Behaviour of Families of Schizophrenic Patients Attending a Teaching Hospital in India: an Indigenous Explanatory Model , 1998 .

[15]  B. Solomon,et al.  Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .

[16]  Allan I. Levey,et al.  Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.

[17]  S. Reda.  Public perceptions of former psychiatric patients in England. , 1996, Psychiatric services.

[18]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[19]  J. Hardy,et al.  New insights into the genetics of Alzheimer's disease. , 1996, Annals of medicine.

[20]  R. Tanzi,et al.  REVIEWThe Gene Defects Responsible for Familial Alzheimer's Disease , 1996, Neurobiology of Disease.

[21]  B. Solomon,et al.  Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Kulhara,et al.  COMPARISON OF THE EXTENT AND PATTERN OF FAMILY BURDEN IN AFFECTIVE DISORDERS AND SCHIZOPHRENIA , 1995, Indian journal of psychiatry.

[23]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[24]  R. Salokangas.  Community Care and Need for Treatment of Schizophrenic Patients in Finland , 1994, British Journal of Psychiatry.

[25]  D. Jones,et al.  The TAPS Project. 11: The Selection of Patients for Reprovision , 1993, British Journal of Psychiatry.

[26]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[27]  P. Crepet.  A Transition Period in Psychiatric Care in Italy Ten Years after the Reform , 1990, British Journal of Psychiatry.

[28]  R. Giel,et al.  Faith-healing and spirit-possession in Ghion, Ethiopia. , 1968, Social science & medicine.

[29]  R. Prince.  The use of Rauwolfia for the treatment of psychoses by Nigerian native doctors. , 1960, The American journal of psychiatry.

[30]  V. Lehtinen,et al.  Patients' expectations from their psychiatric community care in Finland , 1998 .

[31]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[32]  G. Wolff,et al.  Public Education for Community Care: a New Approach , 1996, European Psychiatry.

[33]  R. Tanzi,et al.  The gene defects responsible for familial Alzheimer's disease. , 1996, Neurobiology of disease.

[34]  M. Knapp,et al.  The costs of accommodation and care. Community provision for former long-stay psychiatric hospital patients. , 1994, European archives of psychiatry and clinical neuroscience.

[35]  W T Carpenter,et al.  The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. , 1984, Schizophrenia bulletin.